Skip to main content

Table 4 Patients treated with a long-term treatment directly preceding canakinumab initiationa,b

From: Reasons for canakinumab initiation among patients with periodic fever syndromes: a retrospective medical chart review from the United States

Treatments directly preceding canakinumab initiation, n (%)

Overall (N=133)

Children (N=65)

Adults (N=68)

PFS subtypes

CAPS (n=52)

TRAPS (n=37)

HIDS/MKD (n=10)

FMF (n=39)

Nonsteroidal anti-inflammatory drugs

37 (27.8)

25 (38.5)

12 (17.6)

19 (36.5)

7 (18.9)

4 (40.0)

9 (23.1)

Colchicine

29 (21.8)

13 (20.0)

16 (23.5)

10 (19.2)

3 (8.1)

2 (20.0)

14 (35.9)

Oral corticosteroids

23 (17.3)

13 (20.0)

10 (14.7)

8 (15.4)

7 (18.9)

1 (10.0)

8 (20.5)

Methotrexate

19 (14.3)

3 (4.6)

16 (23.5)

5 (9.6)

8 (21.6)

0 (0.0)

6 (15.4)

Corticosteroid injection

7 (5.3)

3 (4.6)

4 (5.9)

0 (0.0)

6 (16.2)

0 (0.0)

1 (2.6)

Thalidomide

1 (0.8)

1 (1.5)

0 (0.0)

1 (1.9)

0 (0.0)

0 (0.0)

0 (0.0)

Biologics

 Anakinra

32 (24.1)

22 (33.8)

10 (14.7)

17 (32.7)

6 (16.2)

3 (30.0)

9 (23.1)

 Adalimumab

12 (9.0)

3 (4.6)

9 (13.2)

4 (7.7)

5 (13.5)

1 (10.0)

3 (7.7)

 Etanercept

9 (6.8)

4 (6.2)

5 (7.4)

3 (5.8)

3 (8.1)

1 (10.0)

2 (5.1)

 Infliximab

6 (4.5)

4 (6.2)

2 (2.9)

1 (1.9)

3 (8.1)

1 (10.0)

1 (2.6)

 Rilonacept

6 (4.5)

2 (3.1)

4 (5.9)

5 (9.6)

0 (0.0)

1 (10.0)

0 (0.0)

 Rituximab

2 (1.5)

0 (0.0)

2 (2.9)

1 (1.9)

0 (0.0)

1 (10.0)

0 (0.0)

 Tocilizumab

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Unknown

2 (1.5)

0 (0.0)

2 (2.9)

1 (1.9)

0 (0.0)

0 (0.0)

1 (2.6)

  1. CAPS cryopyrin-associated periodic syndromes, FMF familial Mediterranean fever, HIDS hyperimmunoglobulin D syndrome, MKD mevalonate kinase deficiency, PFS periodic fever syndrome, TRAPS tumor necrosis factor receptor-associated periodic syndrome
  2. Notes:
  3. aExcluding patients who did not receive this line of therapy, and patients who received canakinumab as first treatment
  4. bTreatment agents used are not mutually exclusive